Lyell Immunopharma, Inc. (LYEL) Dividend History

Company News

• Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

  Lyell Immunopharma announced positive clinical data for its lead product candidate LYL314, an autologous dual-targeting CD19/CD20 CAR T-cell therapy, in the treatment of relapsed and/or refractory large B-cell lymphoma. The data showed high rates of durable complete responses in patients treated in the third- or later-line setting.

  GlobeNewswire Inc.
• Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

  Lyell Immunopharma announced the acquisition of ImmPACT Bio, a clinical-stage biotechnology company, to strengthen its pipeline of next-generation CAR T-cell therapies. Lyell will prioritize the development of ImmPACT's lead program, IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate, and discontinue the development of some of its own programs.

  Benzinga
• Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know

  Does Lyell Immunopharma (LYEL) have what it takes to be a top stock pick for momentum investors? Let's find out.

  Zacks Investment Research
• Why Shares of Lyell Immunopharma Jumped This Week

  The company gave a presentation regarding its lead therapy to treat solid tumors.

  The Motley Fool
• 3 Red Hot Penny Stocks To Watch Before Next Week, Time To Buy?

  Penny stocks to watch. The post 3 Red Hot Penny Stocks To Watch Before Next Week, Time To Buy? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: MVIS POWW